Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development

HOUSTON, Feb. 7, 2019 -- (Healthcare Sales & Marketing Network) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hema... Biopharmaceuticals, Oncology, Personnel Marker Therapeutics, immunotherapy, immunotherapeutic
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news